Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia

European Journal of Pharmacology
R E See, G Ellison


Rats were administered haloperidol, clozapine, raclopride, or no drug for either 28 days or 8 months and then withdrawn from drug treatment for 3 weeks. Oral movements were repeatedly recorded, both by a human observer and by a computerized video analysis system which determined mouth openings and closings, or computer-scored movelets (CSMs). Four weeks of neuroleptic administration produced no changes in CSMs in any drug-treated group. Long-term administration induced distinctively different patterns of oral activity in the three drug groups, both in number of CSMs and the form of these movements. The oral movements which developed in the haloperidol-treated rats fit a previously described syndrome of late-onset oral dyskinesias which increased upon drug withdrawal. The clozapine- and raclopride-treated rats did not show the increased oral movements seen in the haloperidol animals, but each exhibited uniquely different CSM characteristics compared to controls. The results from this rodent model imply that haloperidol, but not clozapine or raclopride, produces late-onset oral dyskinesias in rats that fit the pattern expected for tardive dyskinesia.


Feb 1, 1978·The Journal of Pharmacy and Pharmacology·P M Laduron, J E Leysen
Jun 11, 1979·Life Sciences·C J Niemegeers, P A Janssen
Jul 23, 1975·Psychopharmacologia·B Costall, R J Naylor
Oct 1, 1986·Pharmacology, Biochemistry, and Behavior·L M GunneP Johansson
Jan 1, 1987·Psychopharmacology·G EllisonJ Kinney
Sep 21, 1987·Life Sciences·A D LevyG Ellison
Jan 1, 1988·Psychopharmacology·U AnderssonE Widerlöv
Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·H HallG Sedvall
Dec 1, 1987·Journal of Clinical Psychopharmacology·J ClaghornG Klerman
Jan 1, 1987·Pharmacology, Biochemistry, and Behavior·E D LevinG Ellison
Jun 1, 1980·The Journal of Pharmacy and Pharmacology·A E TheodorouC D Marsden
Jan 1, 1984·Acta Psychiatrica Scandinavica. Supplementum·J Gerlach, D E Casey
Jul 1, 1984·Pharmacology, Biochemistry, and Behavior·A Robertson, C MacDonald


Jan 1, 1995·Journal of Neural Transmission. General Section·T KakigiC A Tamminga
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Feb 23, 1993·European Journal of Pharmacology·F I TaraziC A Tamminga
Jul 1, 1996·Physiology & Behavior·R E SteinpreisA Harrington
Feb 1, 1996·Pharmacology, Biochemistry, and Behavior·M F EganT M Hyde
Apr 4, 1998·European Journal of Pharmacology·W M Meil, M D Schechter
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Dec 21, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eva RomeroJosé Borrell
Dec 17, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Tadashi IshibashiHiroshi Nakamura
Jul 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·S A Factor, J H Friedman
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo

Related Concepts

Behavior, Animal
Water Consumption
Dyskinesia, Medication-Induced
Fourier Transform
August Rats

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here